Markets

Colorectal cancer biotech Cancer Prevention Pharmaceuticals files for a $29 million IPO

Cancer Prevention Pharmaceuticals, which is developing treatments for colorectal cancer risk factors, filed on Wednesday with the SEC to raise up to $29 million in an initial public offering.

The Tucson, AZ-based company, which was founded in 2009 and booked $4 million in sales for the 12 months ended September 30, 2015, plans to list on the NYSE under the symbol CPP. Cancer Prevention Pharmaceuticals filed confidentially on 9/4/2015. Aegis Capital Corp. is the sole bookrunner on the deal. No pricing terms were disclosed.

The article Colorectal cancer biotech Cancer Prevention Pharmaceuticals files for a $29 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos